Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Reports 18 Percent Increase in Q2 Revenues

NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics on Thursday reported an 18 percent year-over-year increase in its second quarter revenues.

In a form 10-Q filed with the US Securities and Exchange Comission, the New York-based company, which went public in June, said that it had revenues of $1.3 million for the three months ended June 30,, compared to $1.1 million in the year-ago quarter.

It also said that it raised net proceeds of about $6.1 million from its IPO.

Its net loss for the second quarter was $3.3 million, or $1.13 per share, compared to a net loss of $539,691, or $.24 per share, a year ago.

The company slashed its R&D spending to $9,023 from $22,820 a year ago, while its SG&A costs were trimmed 2 percent to $525,465 from $537,403. Signal Genetics said that the decrease in R&D costs resulted from the abandonment of certain research projects that were deemed unviable.

The company finished the quarter with $7.7 million in cash and cash equivalents.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.